174 related articles for article (PubMed ID: 36889294)
21. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Kumar SK; Harrison SJ; Cavo M; de la Rubia J; Popat R; Gasparetto C; Hungria V; Salwender H; Suzuki K; Kim I; Punnoose EA; Hong WJ; Freise KJ; Yang X; Sood A; Jalaluddin M; Ross JA; Ward JE; Maciag PC; Moreau P
Lancet Oncol; 2020 Dec; 21(12):1630-1642. PubMed ID: 33129376
[TBL] [Abstract][Full Text] [Related]
23. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H; Mai EK; Bertsch U; Fenk R; Nievergall E; Tichy D; Besemer B; Dürig J; Schroers R; von Metzler I; Hänel M; Mann C; Asemissen AM; Heilmeier B; Weinhold N; Huhn S; Kriegsmann K; Luntz SP; Holderried TAW; Trautmann-Grill K; Gezer D; Klaiber-Hakimi M; Müller M; Khandanpour C; Knauf W; Scheid C; Munder M; Geer T; Riesenberg H; Thomalla J; Hoffmann M; Raab MS; Salwender HJ; Weisel KC;
Lancet Haematol; 2022 Nov; 9(11):e810-e821. PubMed ID: 36328040
[TBL] [Abstract][Full Text] [Related]
24. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Laubach JP; Moslehi JJ; Francis SA; San Miguel JF; Sonneveld P; Orlowski RZ; Moreau P; Rosiñol L; Faber EA; Voorhees P; Mateos MV; Marquez L; Feng H; Desai A; van de Velde H; Elliott J; Shi H; Dow E; Jobanputra N; Esseltine DL; Niculescu L; Anderson KC; Lonial S; Richardson PG
Br J Haematol; 2017 Aug; 178(4):547-560. PubMed ID: 28466536
[TBL] [Abstract][Full Text] [Related]
25. Old and new generation proteasome inhibitors in multiple myeloma.
Montefusco V; Mussetti A; Salas MQ; Martinelli G; Cerchione C
Panminerva Med; 2020 Dec; 62(4):193-206. PubMed ID: 32957744
[TBL] [Abstract][Full Text] [Related]
26. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
27. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
Danhof S; Schreder M; Rasche L; Strifler S; Einsele H; Knop S
Eur J Haematol; 2016 Jul; 97(1):25-32. PubMed ID: 26331915
[TBL] [Abstract][Full Text] [Related]
28. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
Cornell RF; Ky B; Weiss BM; Dahm CN; Gupta DK; Du L; Carver JR; Cohen AD; Engelhardt BG; Garfall AL; Goodman SA; Harrell SL; Kassim AA; Jadhav T; Jagasia M; Moslehi J; O'Quinn R; Savona MR; Slosky D; Smith A; Stadtmauer EA; Vogl DT; Waxman A; Lenihan D
J Clin Oncol; 2019 Aug; 37(22):1946-1955. PubMed ID: 31188726
[TBL] [Abstract][Full Text] [Related]
29. Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System.
Mina SA; Muhsen IN; Burns EA; Sarfraz H; Pingali SR; Xu J; Hashmi SK
Turk J Haematol; 2021 Aug; 38(3):218-221. PubMed ID: 34190655
[TBL] [Abstract][Full Text] [Related]
30. Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS).
Buck B; Kellett E; Addison D; Vallakati A
J Saudi Heart Assoc; 2022; 34(3):134-141. PubMed ID: 36127934
[TBL] [Abstract][Full Text] [Related]
31. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Voorhees PM; Suman VJ; Tuchman SA; Laubach JP; Hassoun H; Efebera YA; Mulkey F; Bova-Solem M; Santo K; Carlisle D; McCarthy PL; Richardson PG
Am J Hematol; 2021 Dec; 96(12):1595-1603. PubMed ID: 34559902
[TBL] [Abstract][Full Text] [Related]
32. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
McBride A; Klaus JO; Stockerl-Goldstein K
Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
[TBL] [Abstract][Full Text] [Related]
33. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Niesvizky R; Martin TG; Bensinger WI; Alsina M; Siegel DS; Kunkel LA; Wong AF; Lee S; Orlowski RZ; Wang M
Clin Cancer Res; 2013 Apr; 19(8):2248-56. PubMed ID: 23447001
[TBL] [Abstract][Full Text] [Related]
34. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Xu W; Sun X; Wang B; Guo H
Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
[TBL] [Abstract][Full Text] [Related]
35. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.
Ntanasis-Stathopoulos I; Terpos E; Dimopoulos MA
Cancer J; 2019; 25(1):2-10. PubMed ID: 30694854
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
Berenson A; Vardanyan S; David M; Wang J; Harutyunyan NM; Gottlieb J; Halleluyan R; Spektor TM; Udd KA; Eshaghian S; Nassir Y; Eades B; Swift R; Berenson JR
Ann Hematol; 2017 Mar; 96(3):449-459. PubMed ID: 27933373
[TBL] [Abstract][Full Text] [Related]
37. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Usmani SZ; Hoering A; Ailawadhi S; Sexton R; Lipe B; Hita SF; Valent J; Rosenzweig M; Zonder JA; Dhodapkar M; Callander N; Zimmerman T; Voorhees PM; Durie B; Rajkumar SV; Richardson PG; Orlowski RZ;
Lancet Haematol; 2021 Jan; 8(1):e45-e54. PubMed ID: 33357482
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
[TBL] [Abstract][Full Text] [Related]
40. The power of proteasome inhibition in multiple myeloma.
Guerrero-Garcia TA; Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Mitsiades C; Anderson KC; Richardson PG
Expert Rev Proteomics; 2018 Dec; 15(12):1033-1052. PubMed ID: 30427223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]